NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic reprogramming therapies.
NewLimit is inventing medicines composed of epigenetic reprogramming factors that restore youthful function in old cells.
NewLimit was co-founded in 2022 by Brian Armstrong and Blake Byers. The company is headquartered in South San Francisco, California.
NewLimit leverages functional assays, single cell multi-omics, functional genomics, pooled perturbation screening, and machine learning to reveal epigenetic features of aging and discover rejuvenating interventions.
NewLimit combines single cell profiling with new cell reprogramming methods that take advantage of molecular barcoding and CRISPR technology to test thousands of hypotheses in a single experiment. This scale accelerates NewLimit’s discovery engine.
NewLimit has built the first versions of these models that infer cell age from cell genomics profiles and effectively predict the age of new cells from an unseen dataset.
NewLimit has raised $105M in its initial funding on Dec 11, 2022. The financing is backed by its founders Brian Armstrong and Blake Byers.